Of liquid biopsies, CTCs, and first-line treatment for mCRPC

A paper to be presented at the Genitourinary Cancers Synposium today, suggests that use of a liquid biopsy and analysis of single circulating tumor cells (CTCs) may be helpful in determining therapy for men with metastatic, castration-resistant prostate cancer (mCRPC). … READ MORE …

Liquid biopsies and CTC assays — the scientific progress continues

A paper in the British Journal of Cancer has offered further validation of the potential roles for liquid biopsies and circulating tumor cells (CTCs) in the management of aggressive forms of prostate cancer (and in related clinical trials). … READ MORE …

Use of CTCs to assess response to abiraterone acetate at 12 weeks on therapy

Back in 2011 we reported a presentation by Scher et al. indicating that circulating tumor cell counts (CTCs) could probably be used to monitor responses to abiraterone acetate (and perhaps other forms of drug therapy) in the treatment of men with metastatic, castration-resistant prostate cancer. … READ MORE …

A compound genetic/genomic and microenvironmental risk classification for localized prostate cancer

As we become more knowledgeable about the underlying genetic and other factors that affect the risk for, and the risk for progression of, apparently localized prostate cancer, we also become more able to predict such risks … but this is a very complex topic. … READ MORE …

The potential promise of BLZ-100 or “tumor paint”

There has been a lot of media interest in the past couple of weeks in a new technology that may be very helpful in enhancing the visibility of cancerous tissues and the ability to differentiate visually between cancerous and healthy tissue. … READ MORE …

Debulking the primary tumor in men diagnosed with metastatic prostate cancer

There has long been an unanswered question about the value of “debulking” of the primary tumor in men who are initially diagnosed with advanced forms of prostate cancer — i.e., surgical removal of the prostate or some form of definitive radiation therapy of the primary tumor. … READ MORE …

Tumor boards, outcomes, and quality of cancer care

If I happened to be a U.S. military veteran with or at risk for cancer (which I am not) or a senior official with the Veterans Administration, I would likely be more than a little distressed by a recent article in the Journal of the National Cancer Institute. … READ MORE …